Dihydroergotamine Nasal Spray [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-06-26 10:10 (461 d 11:25 ago) – Posting: # 20361
Views: 1,708

Hi NK,

» The guidance specified that "baseline corrected PK data of AUC and Cmax should be used for bio-equivalence calculation"
» As per my understanding, Dihydroergotamine is neither endogenous …

Correct.

» … nor available in the diet, …

Oh yes! Even when, it would practically not absorbed.

» … then why baseline value is required?

IMHO, a bizarre idea. Ask the FDA.

» If it is required, …

It is. If you would deviate from a guidance without a controlled correspondence you risk an RtR.

» … what should be baseline sampling time points (-1h or -30 min or -15 min ...)?

The FDA’s general approach for a stable baseline is subtracting the mean of {-1 h, -0.5 h, pre-dose}. In your case likely it would be BQL anyhow. ;-)

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,086 posts in 4,398 threads, 1,468 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Tuesday 21:36 CEST (Europe/Vienna)

To know the history of science is to recognize the mortality
of any claim to universal truth.    Evelyn Fox Keller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5